Semaglutide vs Tirzepatide: Key Differences Men Should Know Before Choosing

Tirzepatide produces meaningfully greater average weight loss than semaglutide — roughly 20–22% of body weight versus 15% — but semaglutide carries more mature cardiovascular outcome data that matters for men with established heart disease. Choosing between them comes down to how much weight you need to lose, your cardiac history, and what your insurance will actually pay.

How the Weight-Loss Numbers Actually Compare

In STEP-1, published in NEJM, semaglutide (Wegovy, 2.4 mg weekly) produced a mean 14.9% body weight reduction over 68 weeks in adults without diabetes [1][6]. In SURMOUNT-1, also published in NEJM, tirzepatide (Zepbound) at its 15 mg dose hit 22.5% average loss over 72 weeks — and 96% of participants on that dose lost at least 5% of body weight [2][3]. For a 250-pound man, that gap translates to roughly 37 lbs versus 56 lbs. That's not a rounding error.

The mechanism explains the gap. Semaglutide is a selective GLP-1 receptor agonist; tirzepatide is a dual GLP-1/GIP agonist. Adding GIP receptor activation appears to amplify insulin sensitivity and fat-mass reduction beyond what GLP-1 signaling alone achieves [5]. SURMOUNT-1 body-composition data showed tirzepatide reduced total fat mass by 33.9% versus 8.2% with placebo — a figure that matters specifically to men carrying visceral fat [2].

For a deeper look at how these two drugs compare on speed of results, see our tirzepatide vs semaglutide for weight loss analysis.

Cardiovascular Evidence and What It Means for Men

This is where semaglutide currently holds a genuine edge. The SELECT trial demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events in men and women with obesity and established cardiovascular disease but without diabetes — a population that maps onto a large slice of the men asking about these drugs. Comparable cardiovascular outcomes data for tirzepatide are still maturing.

Ozempic's FDA label already includes an indication for reducing cardiovascular death, nonfatal MI, and nonfatal stroke in adults with type 2 diabetes and established CVD [7]. For men with a prior heart attack or significant coronary disease, semaglutide's proven MACE reduction is a substantive clinical argument — not just a tie-breaker. If you're in that category, talk to your cardiologist before defaulting to tirzepatide based on weight-loss numbers alone.

Men interested in exploring either option with a supervised provider can review vetted telehealth programs at Marek Health, which offers both tirzepatide and semaglutide protocols with ongoing lab monitoring.

Practical Tradeoffs: Side Effects, Muscle, and Cost

Both drugs share a GLP-1 side-effect profile — nausea, constipation, delayed gastric emptying — most pronounced during dose escalation. FDA labeling for both carries the theoretical thyroid C-cell tumor warning under the GLP-1 class REMS requirement. Neither is appropriate for men with a personal or family history of medullary thyroid carcinoma.

The lean-mass question matters to men who train. Both drugs reduce fat-free mass as a predictable consequence of sustained caloric deficit, not direct muscle catabolism [4]. Resistance training and adequate protein intake blunt the effect — this is not a reason to avoid these medications, but it's a reason to structure your protocol around the gym, not away from it. For the full picture on compounded options, our compounded semaglutide review covers what the evidence shows on cost and bioequivalence.

On cost: branded Wegovy and Zepbound both run $900–$1,400/month without insurance. Generic semaglutide and generic tirzepatide from 503A/503B compounding pharmacies are substantially cheaper, though supply and regulatory status fluctuate. If cost is your primary constraint, that reality shapes the choice as much as the clinical data does. Explore your weight management treatment options to compare supervised program structures side by side.

Frequently asked questions

Which drug causes more weight loss — semaglutide or tirzepatide?

Tirzepatide produces greater average weight loss than semaglutide across comparable trial durations. SURMOUNT-1 showed mean losses of up to 22.5% at the 15 mg dose versus roughly 14.9% for semaglutide 2.4 mg in STEP-1 [2][6]. Individual results vary, and both drugs require sustained lifestyle changes to maintain results after stopping.

Is semaglutide or tirzepatide better for men with heart disease?

Semaglutide currently has stronger cardiovascular outcome data for men with established heart disease. The SELECT trial demonstrated reduced major adverse cardiovascular events with semaglutide in patients with obesity but without diabetes, and Ozempic carries an FDA-approved MACE-reduction indication for type 2 diabetes patients with CVD [7]. Tirzepatide's cardiovascular outcomes trials are ongoing as of mid-2026.

Can men use compounded versions of these drugs to save money?

Yes — compounded semaglutide and compounded tirzepatide are available through licensed 503A and 503B pharmacies at significantly lower cost than branded Wegovy or Zepbound. Regulatory status has been contested, so sourcing through a supervised telehealth provider matters for both quality assurance and ongoing dose management. Check current availability through our weight management provider directory.